SPRB SPRUCE BIOSCIENCES, INC.

Nasdaq www.sprucebiosciences.com


$ 154.85 $ -0.95 (-0.62 %)    

Friday, 17-Oct-2025 11:37:19 EDT
QQQ $ 598.67 $ 1.06 (0.18 %)
DIA $ 459.93 $ 0.64 (0.14 %)
SPY $ 660.09 $ 0.58 (0.09 %)
TLT $ 91.18 $ -0.05 (-0.05 %)
GLD $ 391.50 $ -5.75 (-1.45 %)
$ 156.61
$ 154.00
$ 153.00 x 94
$ 155.35 x 1
$ 153.05 - $ 154.70
$ 0.10 - $ 240.00
118,507
na
88.18M
$ 5.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 04-15-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-18-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-16-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-14-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-12-2021 03-31-2021 10-Q
19 03-22-2021 12-31-2020 10-K
20 11-18-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 kenneth-griffin-reports-999-passive-stake-in-spruce-biosciences-inc-as-of-oct-9

-SEC Filing

 reported-earlier-spruce-biosciences-reveals-500m-private-placement-financing

Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel ...

 spruce-biosciences-sprb-stock-jumps-30-after-hours-following-red-hot-rally-on-monday-heres-why

Spruce Biosciences shares soared after the FDA granted Breakthrough Therapy Designation to its lead treatment for Sanfilippo Sy...

 spruce-biosciences-stock-is-soaring-today-heres-why

Shares of Spruce Biosciences, Inc. (NASDAQ: SPRB) are surging Monday after the biotech company shared an important regulatory u...

 spruce-biosciences-says-fda-grants-breakthrough-therapy-designation-to-tralesinidase-alfa-enzyme-replacement-therapy-for-treatment-of-sanfilippo-syndrome-type-b

Breakthrough Therapy Designation Supported by Integrated Long-Term Clinical Data Demonstrating Normalization in Cerebral Spinal...

 spruce-biosciences-to-resume-trading-on-nasdaq-capital-market-at-market-open-on-september-15-under-ticker-symbol-sprb

Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel ...

 spruce-biosciences-q2-eps-350-beats-1913-estimate

Spruce Biosciences (NASDAQ:SPRB) reported quarterly losses of $(3.50) per share which beat the analyst consensus estimate of $(...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION